Starling Oncology, Inc.(STLN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$3.5
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for STLN

11/13/2026: STLN (1-star) is currently NOT-A-BUY. Pass it for now.

The Oncology Institute, Inc. (STLN) is a community-based provider of oncology and hematology services that uses a value-based care model to improve patient outcomes. Its core strengths include a unique clinical trial network and a cost-effective outpatient delivery system. The company’s growth story hinges on expanding its geographic footprint and capturing a larger share of the value-based care market. However, investors face notable risks, including persistent net losses, execution challenges in scaling clinic operations, and intense competition from large hospital systems. It may best suit risk-tolerant investors willing to monitor the company’s progress toward profitability and operational efficiency over the coming years.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers a unique value-based care model, but growth is hampered by persistent losses and capital constraints.
Momentum investorWeak fitThe stock has largely struggled with downward momentum, making it a poor fit until a clear fundamental upturn occurs.
Value investorWeak fitThe lack of consistent profitability makes valuation difficult to justify based on traditional P/E or cash flow metrics.
Dividend investorWeak fitThe company does not pay a dividend and requires all available capital for operational scaling.
Low-risk investorWeak fitThe high volatility and operational execution risks make this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock's small-cap nature and growth-stage status contribute to significant price swings.
Valuation riskHighProfitability remains elusive, making current valuation levels highly sensitive to growth assumptions.
Competition risk (Hospital systems)Medium / highLarge, well-capitalized hospital systems have significant advantages in patient referral networks.
Business qualityMediumWhile the value-based model is innovative, the company's business quality is still being proven at scale.
Dividend incomeLow / noneInvestors should not expect income from this stock in the foreseeable future.
Execution riskHighScaling a multi-state oncology practice while managing complex value-based contracts is operationally demanding.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 356.97M USD
Price to earnings Ratio -
1Y Target Price 9.25
Price to earnings Ratio -
1Y Target Price 9.25
Volume (30-day avg) 3.4M shares
Beta 0.41
52 Weeks Range 2.32 - 7.13
Updated Date 11/14/2026
52 Weeks Range 2.32 - 7.13
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.26

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Care Facilities

BUY participation
88.9%
Active BUY / eligible
8 / 9
30-Day BUY Count Change
+6

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 9.41%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
STLN receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
STLN has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, moderate earnings growth (+6.3%) and solid revenue growth (+27.8%) are partially offset by weak cash generation (FCF margin -5.5%), weak profitability (net margin -12.1%).

Financial Health Rating

★★★★★
STLN's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 25.4%). Profitability is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is STLN's strongest growth driver at +27.8% FY2025 versus FY2024 (solid, 4 stars). Earnings growth (+6.3%, moderate) and free-cash-flow growth (+8.4%, moderate) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 48.2% and approximately 90.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 15.19% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 4.66%
Deerfield Management Co 3.30%
Vanguard Capital Management, LLC 3.20%
JOSH ARNOLD INVESTMENT CONSULTANT, LLC 2.42%
Geode Capital Management, LLC 1.86%

Unit Economics (Per $1K Revenue)

★★★★★
STLN generates approximately $152 of gross profit, $-72 of operating income, and $-55 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.22%

Quantitative Style Profile

★★★★★
STLN has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Oncology ServicesProfessional fees and facility fees from chemotherapy, hematology, and infusion services.The company gets paid by health insurance plans and government programs for treating cancer patients in their clinics.
Clinical ResearchFees from pharmaceutical companies to run clinical trials for new cancer drugs.The company earns revenue by acting as a site for pharmaceutical research, helping test new and potentially breakthrough treatments.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 422.80M
Price to Sales(TTM) 0.58
Enterprise Value 422.80M
Price to Sales(TTM) 0.58
Enterprise Value to Revenue 0.68
Enterprise Value to EBITDA 8.53
Shares Outstanding 101.99M
Shares Floating 91.77M
Shares Outstanding 101.99M
Shares Floating 91.77M
Percent Insiders 15.19
Percent Institutions 48.22

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.